Semaglutide seems to be more effective the other GLP-1Ras
Authors:
- 1 December 2017
- journal article
- editorial
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 5 (24) , 505
Abstract
Semaglutide seems to be more effective the other GLP-1RasKeywords
This publication has 31 references indexed in Scilit:
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trialThe Lancet, 2017
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2017
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trialThe Lancet Diabetes & Endocrinology, 2017
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue SemaglutideJournal of Medicinal Chemistry, 2015
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trialDiabetes, Obesity and Metabolism, 2013
- Regulation of Intestinal Chylomicron Production by Glucagon-Like PeptidesCardiovascular & Hematological Disorders-Drug Targets, 2012
- Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weightDiabetes, Obesity and Metabolism, 2012
- Glucagon-like peptide-1 prevents beta cell glucolipotoxicityDiabetologia, 2004
- Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2003